Fuso Pharmaceutical Industries,Ltd. (4538.T)
JPY 2388.0
(0.55%)
JPY 2388.0
(0.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.67 Billion JPY | -22.11% |
| 2022 | 4.63 Billion JPY | 2.91% |
| 2021 | 4.46 Billion JPY | -4.81% |
| 2020 | 4.79 Billion JPY | 34.42% |
| 2019 | 3.45 Billion JPY | 4.59% |
| 2018 | 3.44 Billion JPY | 18.38% |
| 2017 | 3.5 Billion JPY | 3.01% |
| 2016 | 3.28 Billion JPY | 52.62% |
| 2015 | 1.85 Billion JPY | -33.23% |
| 2014 | 2.78 Billion JPY | -41.23% |
| 2013 | 4.76 Billion JPY | -15.74% |
| 2012 | 5.56 Billion JPY | 140.15% |
| 2011 | 2.15 Billion JPY | -43.06% |
| 2010 | 3.37 Billion JPY | 50.79% |
| 2009 | 3.1 Billion JPY | -61.1% |
| 2008 | 2.29 Billion JPY | 7.06% |
| 2007 | 2.56 Billion JPY | -16.04% |
| 2006 | 983 Million JPY | 3.09% |
| 2005 | 204 Million JPY | -15.76% |
| 2004 | 3.53 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.72 Billion JPY | 814.46% |
| 2023 Q2 | 507 Million JPY | -21.27% |
| 2023 Q1 | 644 Million JPY | 194.06% |
| 2023 Q4 | 213 Million JPY | -83.64% |
| 2023 FY | - JPY | -22.11% |
| 2023 Q3 | 1.3 Billion JPY | 156.8% |
| 2022 Q2 | 630 Million JPY | -7.22% |
| 2022 Q4 | 219 Million JPY | -70.0% |
| 2022 Q1 | 679 Million JPY | 2852.17% |
| 2022 Q3 | 730 Million JPY | 15.87% |
| 2022 FY | - JPY | 2.91% |
| 2021 Q4 | 23 Million JPY | -96.83% |
| 2021 FY | - JPY | -4.81% |
| 2021 Q3 | 725 Million JPY | 13.28% |
| 2021 Q1 | 663 Million JPY | 776.53% |
| 2021 Q2 | 640 Million JPY | -3.47% |
| 2020 Q4 | -98 Million JPY | -114.12% |
| 2020 Q1 | 1.08 Billion JPY | 1226.04% |
| 2020 Q2 | 756 Million JPY | -30.06% |
| 2020 FY | - JPY | 34.42% |
| 2020 Q3 | 694 Million JPY | -8.2% |
| 2019 FY | - JPY | 4.59% |
| 2019 Q4 | -96 Million JPY | -118.01% |
| 2019 Q2 | 134 Million JPY | -79.42% |
| 2019 Q1 | 651 Million JPY | 1413.95% |
| 2019 Q3 | 533 Million JPY | 297.76% |
| 2018 Q3 | 636 Million JPY | 64.34% |
| 2018 FY | - JPY | 18.38% |
| 2018 Q1 | 412 Million JPY | 2646.67% |
| 2018 Q2 | 387 Million JPY | -6.07% |
| 2018 Q4 | 43 Million JPY | -93.24% |
| 2017 Q1 | 327 Million JPY | 475.86% |
| 2017 FY | - JPY | 3.01% |
| 2017 Q3 | 464 Million JPY | 153.55% |
| 2017 Q2 | 183 Million JPY | -44.04% |
| 2017 Q4 | 15 Million JPY | -96.77% |
| 2016 Q1 | 412 Million JPY | 240.14% |
| 2016 FY | - JPY | 52.62% |
| 2016 Q4 | -87 Million JPY | -127.36% |
| 2016 Q3 | 318 Million JPY | 78.65% |
| 2016 Q2 | 178 Million JPY | -56.8% |
| 2015 FY | - JPY | -33.23% |
| 2015 Q4 | -294 Million JPY | -174.81% |
| 2015 Q3 | 393 Million JPY | 435.9% |
| 2015 Q2 | -117 Million JPY | -132.87% |
| 2015 Q1 | 356 Million JPY | 1418.52% |
| 2014 Q3 | 462 Million JPY | 164.0% |
| 2014 Q4 | -27 Million JPY | -105.84% |
| 2014 FY | - JPY | -41.23% |
| 2014 Q1 | 248 Million JPY | 66.44% |
| 2014 Q2 | 175 Million JPY | -29.44% |
| 2013 Q2 | 689 Million JPY | -30.33% |
| 2013 Q4 | 149 Million JPY | -85.28% |
| 2013 FY | - JPY | -15.74% |
| 2013 Q1 | 989 Million JPY | 89.46% |
| 2013 Q3 | 1.01 Billion JPY | 46.88% |
| 2012 Q3 | 1.27 Billion JPY | 36.94% |
| 2012 Q4 | 522 Million JPY | -59.19% |
| 2012 Q1 | 1.11 Billion JPY | 808.92% |
| 2012 FY | - JPY | 140.15% |
| 2012 Q2 | 934 Million JPY | -16.08% |
| 2011 Q1 | -101 Million JPY | -113.29% |
| 2011 Q2 | 205 Million JPY | 302.97% |
| 2011 Q3 | 496 Million JPY | 141.95% |
| 2011 Q4 | -157 Million JPY | -131.65% |
| 2011 FY | - JPY | -43.06% |
| 2010 Q3 | 1.32 Billion JPY | 9.5% |
| 2010 Q2 | 1.21 Billion JPY | 52.33% |
| 2010 FY | - JPY | 50.79% |
| 2010 Q4 | 760 Million JPY | -42.68% |
| 2010 Q1 | 795 Million JPY | 23.26% |
| 2009 Q1 | 619 Million JPY | -86.24% |
| 2009 Q4 | 645 Million JPY | -25.26% |
| 2009 Q3 | 863 Million JPY | 47.77% |
| 2009 Q2 | 584 Million JPY | -5.65% |
| 2009 FY | - JPY | -61.1% |
| 2008 Q2 | 160 Million JPY | 0.0% |
| 2008 FY | - JPY | 7.06% |
| 2008 Q4 | 4.49 Billion JPY | 337.65% |
| 2008 Q3 | 1.02 Billion JPY | 542.5% |
| 2007 FY | - JPY | -16.04% |
| 2006 FY | - JPY | 3.09% |
| 2005 FY | - JPY | -15.76% |
| 2004 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 39.047% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 99.58% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 101.306% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 98.034% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -542.764% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 89.887% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 70.082% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 96.441% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -183.836% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 79.989% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 59.1% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -161.582% |
| Tsumura & Co. | 30.77 Billion JPY | 88.074% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 80.395% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | 30.374% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 89.672% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 46.672% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 79.054% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 64.355% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 197.867% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 51.41% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 614.006% |
| MedRx Co., Ltd | -884.51 Million JPY | 514.916% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 33.71% |
| Solasia Pharma K.K. | -635 Million JPY | 677.953% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 254.596% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 59.948% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 90.047% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 781.79% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 85.8% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | 28.062% |